Evaluation of a Developed MRI-Guided Focused Ultrasound System in 7 T Small Animal MRI and Proof-of-Concept in a Prostate Cancer Xenograft Model to Improve Radiation Therapy
Authors:
- Xinrui ZhangXZXinrui Zhang
- Sebastian GreiserSGSebastian Greiser
- Upasana RoyURUpasana Roy
- Franziska LangeFLFranziska Lange
- Robbert van GorkumRGRobbert van Gorkum
- Marc FournelleMFMarc Fournelle
- Daniel SpeicherDSDaniel Speicher
- Steffen TretbarSTSteffen Tretbar
- Andreas MelzerAndreas Melzer
- Lisa LandgrafLLLisa Landgraf
Open Access
Abstract
Focused ultrasound (FUS) can be used to physiologically change or destroy tissue in a non-invasive way. A few commercial systems have clinical approval for the thermal ablation of solid tumors for the treatment of neurological diseases and palliative pain management of bone metastases. However, the thermal effects of FUS are known to lead to various biological effects, such as inhibition of repair of DNA damage, reduction in tumor hypoxia, and induction of apoptosis. Here, we studied radiosensitization as a combination therapy of FUS and RT in a xenograft mouse model using newly developed MRI-compatible FUS equipment. Xenograft tumor-bearing mice were produced by subcutaneous injection of the human prostate cancer cell line PC-3. Animals were treated with FUS in 7 T MRI at 4.8 W/cm2 to reach ~45 °C and held for 30 min. The temperature was controlled via fiber optics and proton resonance frequency shift (PRF) MR thermometry in parallel. In the combination group, animals were treated with FUS followed by X-ray at a single dose of 10 Gy. The effects of FUS and RT were assessed via hematoxylin-eosin (H&E) staining. Tumor proliferation was detected by the immunohistochemistry of Ki67 and apoptosis was measured by a TUNEL assay. At 40 days follow-up, the impact of RT on cancer cells was significantly improved by FUS as demonstrated by a reduction in cell nucleoli from 189 to 237 compared to RT alone. Inhibition of tumor growth by 4.6 times was observed in vivo in the FUS + RT group (85.3%) in contrast to the tumor volume of 393% in the untreated control. Our results demonstrated the feasibility of combined MRI-guided FUS and RT for the treatment of prostate cancer in a xenograft mouse model and may provide a chance for less invasive cancer therapy through radiosensitization.Keywords
Funding Information
- Bundesministerium für Forschung, Technologie und Raumfahrt (03Z1L511)
This publication has 37 references indexed in Scilit:
- Radiosensitization in prostate cancer: mechanisms and targetsBMC Urology, 2013
- Cancer and Radiation Therapy: Current Advances and Future DirectionsInternational Journal of Medical Sciences, 2012
- A Preclinical In Vivo Investigation of High-Intensity Focused Ultrasound Combined with RadiotherapyUltrasound in Medicine & Biology, 2011
- A NADPH Oxidase–Dependent Redox Signaling Pathway Mediates the Selective Radiosensitization Effect of Parthenolide in Prostate Cancer CellsCancer Research, 2010
- Real‐time MR thermometry for monitoring HIFU ablations of the liverMagnetic Resonance in Medicine, 2009
- Hyperthermia – description of a method and a review of clinical applicationsReports of Practical Oncology and Radiotherapy, 2007
- Hyperthermia: a Potent Enhancer of RadiotherapyClinical Oncology, 2007
- Molecular markers of outcome after radiotherapy in patients with prostate carcinomaCancer, 2003
- The Process and Development of Image-Guided ProceduresAnnual Review of Biomedical Engineering, 2001
- Ex vivo tissue‐type independence in proton‐resonance frequency shift MR thermometryMagnetic Resonance in Medicine, 1998